Interleukin 38 as a Biomarker for Metabolic Syndrome in Psoriatic Patients
1 other identifier
observational
96
0 countries
N/A
Brief Summary
case control study to compare level of interleukin 38 in patients with psoriasis and patients with metabolic syndrome with healthy control subjects
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Oct 2021
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 20, 2021
CompletedStudy Start
First participant enrolled
October 1, 2021
CompletedFirst Posted
Study publicly available on registry
October 13, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2022
CompletedOctober 21, 2021
October 1, 2021
7 months
September 20, 2021
October 13, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
measure plasma level of interleukin 38 in all groups
level of interleukin 38 will be measured and compared in all groups to asses the relationship between this interleukin and metabolic syndrome in psoriatic patients
through study completion an average of 18 months
Study Arms (4)
Group 1 (Psoriasis only)
contains 24 psoriatic patients, Psoriasis Area Severity Index will be measured, also waist circumference, body mass index, blood pressure, fasting blood glucose and fasting lipid profile and finally: plasma level of interleukin 38
Group 2 (Psoriasis and metabolic syndrome)
contains 24 psoriatic patients with metabolic syndrome. Psoriasis Area Severity Index will be measured metabolic syndrome is diagnosed after measuring waist circumference, body mass index, blood pressure, fasting blood glucose and fasting lipid profile finally: plasma level of interleukin 38
Group 3 (Metabolic syndrome only)
contains 24 patients with metabolic syndrome only. full dermatological examination to exclude psoriasis and other inflammatory skin disorders metabolic syndrome is diagnosed after measuring waist circumference, body mass index, blood pressure, fasting blood glucose and fasting lipid profile finally: plasma level of interleukin 38
Group 4 (Healthy Controls)
contains 24 healthy control subjects full dermatological examination to exclude psoriasis and other inflammatory skin disorders metabolic syndrome is excluded after measuring waist circumference, body mass index, blood pressure, fasting blood glucose and fasting lipid profile finally: plasma level of interleukin 38
Interventions
draw 5 ml of venous blood into EDTA tubes and centrifuged then plasma is separated for test
Eligibility Criteria
people attending the Dermatology Outpatient Clinics of Sohag University Hospital.
You may qualify if:
- specific to each group
You may not qualify if:
- Patient refusal. Age \<18 years Pregnancy Lactation smoking Infections. Patients with other inflammatory skin disorders use of antioxidant and anti-inflammatory drugs patients on treatment for psoriasis
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Sohag Universitylead
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
yomna a abdellatif, MBBCH
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- resident doctor in dermatology venereology and andrology department in sohag university hospital
Study Record Dates
First Submitted
September 20, 2021
First Posted
October 13, 2021
Study Start
October 1, 2021
Primary Completion
May 1, 2022
Study Completion
December 1, 2022
Last Updated
October 21, 2021
Record last verified: 2021-10